The anti-PD-1 antibodies nivolumab and pembrolizumab as well as the anti-cytotoxic T-lymphocyte associated protein (CTLA)-4 antibody ipilimumab are all currently being investigated in different phases for patients with HCC. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.